content: <PAGE>  1
                   SECURITIES AND EXCHANGE COMMISSION
      
                        Washington, D.C.  20549
      
                             FORM 8-K
      
                           CURRENT REPORT
      
      
                   PURSUANT TO SECTION 13 OR 15(d) OF
                   THE SECURITIES EXCHANGE ACT OF 1934
      
      
      Date of Report (Date of earliest event reported) -July 12, 1996
      
                 ADVANCED VIRAL RESEARCH CORP.            
         (Exact name of registrant as specified in its charter)
      
           Delaware                33-2262-A           59-2646820       
      (State or other juris-    (Commission File     (IRS Employer
      diction of incorporation)    Number)         Identification No.)
      
                 1250 East Hallandale Beach Blvd.
                 Suite 501,
                 Hallandale, Florida                    33009   
         (Address or principal executive offices)     (Zip Code)
      
      
      Registrant's telephone number, including area code: (954)458-7636
      
      
                             None
      (Former name or former address, if changed since last report)
    <PAGE>  2
    
      Item 1.    Changes in Control of Registrant
      
            Not Applicable
      
      Item 2.    Acquisition or Disposition of Assets
      
            Not Applicable
      
      Item 3.    Bankruptcy or Receivership
      
            Not Applicable
     
      Item 4.    Changes in Registrant's Certifying Accountant
      
            Not Applicable
      
      Item 5.    Other Events
    
            On July 11, 1996, Advanced Viral Research Corp. (the
    "Company") entered into an Addendum to Agreement (the "Addendum")
    with Avix International Pharmaceutical Corp. ("Avix") providing for
    certain amendments to the Company's distribution arrangement with
    Avix.  Among other things, the Addendum provides that Avix shall be
    the exclusive distributor of the Company's drug Reticulose in the
    territory consisting of China, Japan, Hong Kong, Taiwan and Macao
    (the "Territory"). No sales of the Company's drug Reticulose have
    been made by the Company in the Territory to date because the
    Company's drug Reticulose is not approved for sale in any of the
    countries in the Territory.  The Addendum further provides that the
    Company has granted to Avix the opportunity to retain the right to
    exclusively distribute the Company's drug Reticulose in the Territory
    (i) through June 1997 so long as Avix pays to the Company $8,000 per
    month during such twelve month period; or (ii) if the Company's drug
    Reticulose is approved for sale in any of the countries in the
    Territory.
    
      Item 6. Resignations of Registrant's Directors
      
              Not Applicable
      
      Item 7. Financial Statements and Exhibits
      
            (a)  Financial statements of business acquired
      
                 None
      
            (b)  Pro forma financial information
      
                 None
      
            (c)  Exhibits
      
                 (1)  Addendum to Agreement dated July 11, 1996 by
    and between Advanced Viral Research Corp. and AVIX International
    Pharmaceutical Corp.
    
    
      Item 8. Change in Fiscal Year
      
              Not Applicable
      
      <PAGE>  3
                             SIGNATURES
      
       Pursuant to the requirements of the Securities Exchange Act of
    1934, the registrant has duly caused this report to be signed on its
    behalf by the undersigned hereunto duly authorized.
      
      
                           ADVANCED VIRAL RESEARCH CORP.           
    
                           (Registrant)
      
      
      
      Dated: July 12, 1996       By:/s/William Bregman
                                       William Bregman
                                       Secretary-Treasurer
      
      
      
      
      <PAGE>  4
                        LIST OF EXHIBITS
      
    
            (1)  Addendum to Agreement dated July 11, 1996 by and
    between Advanced Viral Research Corp. and AVIX International
    Pharmaceutical Corp.
metadata_documents: [{"type": "8-K", "sequence": "1", "secsgml_size_bytes": 3954}]
metadata_filer: {"company-data": {"conformed-name": "ADVANCED VIRAL RESEARCH CORP", "cik": "0000786623", "assigned-sic": "2834", "irs-number": "592646820", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "033-02262-A", "film-number": "96594178"}, "business-address": {"street1": "1250 E HALLANDALE BEACH BLVD", "street2": "STE 501", "city": "HALLANDALE", "state": "FL", "zip": "33009", "phone": "9544587636"}}
text: 1
                   SECURITIES AND EXCHANGE COMMISSION
      
                        Washington, D.C.  20549
      
                             FORM 8-K
      
                           CURRENT REPORT
      
      
                   PURSUANT TO SECTION 13 OR 15(d) OF
                   THE SECURITIES EXCHANGE ACT OF 1934
      
      
      Date of Report (Date of earliest event reported) -July 12, 1996
      
                 ADVANCED VIRAL RESEARCH CORP.            
         (Exact name of registrant as specified in its charter)
      
           Delaware                33-2262-A           59-2646820       
      (State or other juris-    (Commission File     (IRS Employer
      diction of incorporation)    Number)         Identification No.)
      
                 1250 East Hallandale Beach Blvd.
                 Suite 501,
                 Hallandale, Florida                    33009   
         (Address or principal executive offices)     (Zip Code)
      
      
      Registrant's telephone number, including area code: (954)458-7636
      
      
                             None
      (Former name or former address, if changed since last report)
  2
    
      Item 1.    Changes in Control of Registrant
      
            Not Applicable
      
      Item 2.    Acquisition or Disposition of Assets
      
            Not Applicable
      
      Item 3.    Bankruptcy or Receivership
      
            Not Applicable
     
      Item 4.    Changes in Registrant's Certifying Accountant
      
            Not Applicable
      
      Item 5.    Other Events
    
            On July 11, 1996, Advanced Viral Research Corp. (the
    "Company") entered into an Addendum to Agreement (the "Addendum")
    with Avix International Pharmaceutical Corp. ("Avix") providing for
    certain amendments to the Company's distribution arrangement with
    Avix.  Among other things, the Addendum provides that Avix shall be
    the exclusive distributor of the Company's drug Reticulose in the
    territory consisting of China, Japan, Hong Kong, Taiwan and Macao
    (the "Territory"). No sales of the Company's drug Reticulose have
    been made by the Company in the Territory to date because the
    Company's drug Reticulose is not approved for sale in any of the
    countries in the Territory.  The Addendum further provides that the
    Company has granted to Avix the opportunity to retain the right to
    exclusively distribute the Company's drug Reticulose in the Territory
    (i) through June 1997 so long as Avix pays to the Company $8,000 per
    month during such twelve month period; or (ii) if the Company's drug
    Reticulose is approved for sale in any of the countries in the
    Territory.
    
      Item 6. Resignations of Registrant's Directors
      
              Not Applicable
      
      Item 7. Financial Statements and Exhibits
      
            (a)  Financial statements of business acquired
      
                 None
      
            (b)  Pro forma financial information
      
                 None
      
            (c)  Exhibits
      
                 (1)  Addendum to Agreement dated July 11, 1996 by
    and between Advanced Viral Research Corp. and AVIX International
    Pharmaceutical Corp.
    
    
      Item 8. Change in Fiscal Year
      
              Not Applicable
  3
                             SIGNATURES
      
       Pursuant to the requirements of the Securities Exchange Act of
    1934, the registrant has duly caused this report to be signed on its
    behalf by the undersigned hereunto duly authorized.
      
      
                           ADVANCED VIRAL RESEARCH CORP.           
    
                           (Registrant)
      
      
      
      Dated: July 12, 1996       By:/s/William Bregman
                                       William Bregman
                                       Secretary-Treasurer
  4
                        LIST OF EXHIBITS
      
    
            (1)  Addendum to Agreement dated July 11, 1996 by and
    between Advanced Viral Research Corp. and AVIX International
    Pharmaceutical Corp.